ARTICLE | Company News
sanofi-aventis, Sunnybrook Health Sciences Center deal
February 21, 2011 8:00 AM UTC
sanofi-aventis received an option from Sunnybrook for exclusive, worldwide rights to develop and commercialize vasculotide. The synthetic, peptide-based growth factor that targets tyrosine kinase rec...